title: [Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis].
abstract: OBJECTIVE
  To analyze antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis.
  
  
  METHODS
  104 patients of hepatitis B virus-related cirrhosis with no previous history of antiviral therapy were treated with entecavir 0.5 mg once daily. 37 patients were taken hepatic histologic examination before and after the treatment.
  
  
  RESULTS
  Mean reductions of serum HBV DNA was 5.1 log10 96 weeks after the treatment, HBV DNA became undetectable in 98.1% patients, and ALT became normal in 80.7% patients; HBeAg seroconversion occurred in 13.9% of the 72 HBeAg positive patients; 61.5% of these patients were infected with genotype C HBV, and 26.9% were infected with genotype B HBV. The genotype of HBV was not associated with the therapeutical effect. Child-pugh score was associated with the progression of the disease: the proportion of patients with disease progression was highest in Child-Pugh C grade patients and lowest in Child-Pugh A grade patients. The level of the HBV DNA load was positively correlated with Knodell HAI score at the baseline and 96 weeks after the treatment.
  
  
  CONCLUSIONS
  Entecavir treatment results in suppression of HBV replication and delayed progression of fibrosis in patients with hepatitis B virus-related cirrhosis.
authors.affiliation: China-Japan Union Hospital of Jilin University, Changchun 130033, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Xu
authors.forename: Jiang-bin
authors.initials: JB
authors.lastname: Wang
authors.forename: Jie
authors.initials: J
authors.lastname: Xu
authors.forename: Jian
authors.initials: J
authors.lastname: Jiao
authors.forename: Yong-gui
authors.initials: YG
authors.lastname: Zhang
authors.forename: Shang-wei
authors.initials: SW
authors.lastname: Ji
authors.forename: Ping
authors.initials: P
authors.lastname: Zhao
authors.forename: Hong-hua
authors.initials: HH
authors.lastname: Guo
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Chang-yu
authors.initials: CY
authors.lastname: Zhou
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood*; D005260:Female; D005838:Genotype; D006147:Guanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006513:Hepatitis B e Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy* / Q000209:etiology / Q000821:virology; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome; D014779:Virus Replication / Q000187:drug effects
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006513:Hepatitis B e Antigens; C413685:entecavir; D006147:Guanine; D000410:Alanine Transaminase